CIPROFLOXACIN CONCENTRATE FOR IN. Key specifications include administration: ORAL, primary_container_type: VIAL, medical_designation_and_grade: UNITED STATES PHARMACOPEIA, total_primary_container_quantity: 60, primary_container_content_quantity: 20.000 MILLILITERS, active_medicament_medicinal_strength: 200.000 MILLIGRAMS CIPROFLOXACIN EQUIVALENT. This product is currently in active production with full OEM support.
This part is cataloged in the Federal Logistics Information System under NSN 6505-01-272-2384, indicating validated use in U.S. government and defense logistics supply chains. Available through authorized enterprise resellers and TPM (Third Party Maintenance) channels.
Verify compatibility with your specific system configuration before ordering.
| administration | ORAL |
| primary_container_type | VIAL |
| medical_designation_and_grade | UNITED STATES PHARMACOPEIA |
| total_primary_container_quantity | 60 |
| primary_container_content_quantity | 20.000 MILLILITERS |
| active_medicament_medicinal_strength | 200.000 MILLIGRAMS CIPROFLOXACIN EQUIVALENT |
| part_name_assigned_by_controlling_agency | CIPROFLOXACIN SUSPENSION 250MG/5ML 100ML AFTER RECONSTITUTION |
| NSN | 6505-01-272-2384 |
| PRIMARY CONTAINER TYPE | BOTTLE |
| ACTIVE MEDICAMENT MEDICINAL STRENGTH | 750.000 MILLIGRAMS CIPROFLOXACIN EQUIVALENT |
| MEDICAL DESIGNATION AND GRADE | UNITED STATES PHARMACOPEIA |
| PART NAME ASSIGNED BY CONTROLLING AGENCY | CIPROFLOXFACIN TABLETS USP 750MG 50S BT |
| PRIMARY CONTAINER CONTENT QUANTITY | 50.000 TABLETS |